SPRB 8-K SEC Filing Analysis

Final — all horizons settled through T+60d

SPRB ▼ -20.62% at T+60d

NEUTRAL call ✗ call lost -20.62% · α vs SPY -32.61% · entry $62.11 → $49.30

Last close $49.32 (close Jun 8) · -20.59% from $62.11 entry

Entry anchored
Mar 6, 03:46 PM ET
via Databento tick

T+1d

+1.09%

call +1.09% · α +1.28%

$62.79

settled 3mo ago

T+5d

-1.87%

call -1.87% · α -0.51%

$60.95

settled 3mo ago

T+20d

+0.06%

call +0.06% · α +2.87%

$62.15

settled 2mo ago

T+60d

-20.62%

call -20.62% · α -32.61%

$49.30

settled 7d ago

Price Chart

Loading chart...

Executive Summary

Spruce Biosciences entered into an at-the-market (ATM) equity offering agreement with Jefferies to sell up to $75 million in common stock, while reporting improved financials with a reduced net loss of $39.0 million in 2025 compared to $53.0 million in 2024. The company also appointed a new Chief Commercial Officer and secured $15 million in loan funding, signaling progress in its drug development pipeline for Sanfilippo Syndrome Type B. However, the ATM offering introduces potential share dilution.

Key Financial Metrics

EPS

$-50.83

Actionable Insight

Monitor the pace of ATM share sales and their impact on stock price, while watching for upcoming BLA submission for TA-ERT in Q4 2026 as a potential catalyst. The reduced R&D expenses and improved cash position suggest more efficient operations, but the equity offering could pressure shares in the short term.

Key Facts

Entered into an ATM equity offering agreement with Jefferies to sell up to $75 million in common stock
Net loss decreased to $39.0 million in 2025 from $53.0 million in 2024
Appointed Dale Hooks as Chief Commercial Officer with a $480,000 base salary and 11,000 RSUs
Secured $15 million in initial funding from a $50 million loan facility with Avenue Capital
Cash and cash equivalents increased to $48.9 million as of December 31, 2025
Research and development expenses decreased to $19.5 million from $46.4 million year-over-year

Financial Impact

Up to $75 million in potential dilution from ATM offering, $15 million in new debt funding, $39.0 million net loss for 2025

dilutiondebtnetLosscash

Risk Factors

Dilution from ATM equity offering could pressure stock price
Dependence on successful BLA approval for TA-ERT in 2026
Execution risk with commercial launch preparations

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-097561
Document: sprb-ex99_1.htm	0001193125-26-097561
Document: sprb-20260309.htm	0001193125-26-097561
Document: sprb-ex10_2.htm	0001193125-26-097561
Document: sprb-ex10_1.htm	0001193125-26-097561
Document: sprb-ex5_1.htm	0001193125-26-097561
Document: 0001193125-26-097561-index-headers.html	0001193125-26-097561
Document: 0001193125-26-097561-index.html	0001193125-26-097561
Document: 0001193125-26-097561.txt	0001193125-26-097561

4 reports for SPRB

T+1T+5T+20T+60

Filters

Reports for SPRB — sortable, filterable
	Type				Now
May 13, 2026 27d ago	8-K MIXED ★ 5/10	$57.55 $48.25	▼ −16.16%	▼ −15.00%	$49.32 (−14.30%)
Apr 21, 2026 7w ago	424B5 NEUTRAL ★ 5/10	$52.36 $56.34	▲ +7.60%	▲ +7.55%	$49.32 (−5.81%)
Apr 20, 2026 7w ago	424B5 NEUTRAL ★ 5/10	$51.69 $54.77	▲ +5.96%	▲ +4.87%	$49.32 (−4.59%)
Mar 9, 2026 13w ago	8-K MIXED ★ 6/10	$62.11 $60.95	▼ −1.87%	▼ −0.51%	$49.32 (−20.59%)

US Market Status

Market Closed — Opens in 7h 21m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access